EMA Authorised: Cerezyme (imiglucerase) — Sanofi B.V.

View source ↗

Summary

EMA authorised Cerezyme (imiglucerase) for Gaucher disease, with Sanofi B.V. listed as the marketing authorization holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gaucher Disease

Drugs mentioned

• CEREZYME (imiglucerase)

Snippet

Status: Authorised. Therapeutic area: Gaucher Disease. MAH: Sanofi B.V.. Decision date: 16/10/2025